Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

• Conditions: Hepatocellular Carcinoma
• Interventions: Procedure: MRI Scan of the Liver enhanced with Eovist

• Registration Number: NCT01341132
• Lead Sponsor: San Francisco Veterans Affairs Medical Center

Brief Summary

This study aims to determine whether or not gadoxetate disodium (Eovist) enhanced magnetic resonance imaging (MRI) has a higher sensitivity for detecting hepatocellular carcinoma (Liver Cancer) comparison to multi-detector computed tomography (CT).

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-04
• Study First Submitted: 2011-04-21
• Study First Submitted QC: 2011-04-21
• Last Update Submitted: 2011-04-21
• Study First Posted: 2011-04-25
• Last Update Posted: 2011-04-25
• Study Start: 2011-05
• Primary Completion: 2012-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• Alpha-feto protein > 400 ng / mL or
• prior ultrasound with mass suspicious for hepatic malignancy or.
• clinical risk of hepatocellular carcinoma or
• prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Exclusion Criteria

• Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement within three months of the MR study
• Previous diagnosis of hepatic malignancy
• Any conditions that would discount the ability to have an MRI scan

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Suspected Liver Disease	MRI Scan of the Liver enhanced with Eovist	1. Alpha-feto protein \> 400 ng / mL or 2. prior ultrasound with mass suspicious for hepatic malignancy or. 3. clinical risk of hepatocellular carcinoma or 4. prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma

Trial Locations

Locations (1)

San Francisco VA Medical Center; 🇺🇸 San Francisco, California, United States